MetaCap

Cartesian Therapeutics (RNAC) vs Vogenx (VOGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cartesian Therapeutics is the larger company by market cap ($187.3 million vs $176.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RNAC-29.22%VOGX-8.69%
+172%+65%-42%
Aug 12, 20261 yearNov 20, 2026
RNAC-30.54%VOGX-19.69%
+138%+50%-39%
Aug 10, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RNAC versus VOGX key metrics
MetricRNACVOGX
Share price$6.14$11.87
Market cap$187.29M$176.33M
1-day change+4.24%-7.30%
YTD return-14.84%—
1-year return-15.19%—
5-year return-92.94%—
EPS (TTM)$-4.78$-0.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.80M—
Revenue growth (YoY)-92.81%—
Net income (latest FY)$-130.30M—
Operating margin-5127.10%—
Net margin-4658.63%—
52-week high$11.00$38.41
52-week low$5.60$11.51
Distance from 52-week high-44.18%-69.10%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+448.37%+363.35%
Average volume139.65K128.78K
Shares outstanding30.50M14.86M
Employees754
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cartesian Therapeutics

RNAC stock →

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About Vogenx

VOGX stock →

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

RNAC vs VOGX FAQ

Which is bigger, Cartesian Therapeutics or Vogenx?

Cartesian Therapeutics (RNAC) is larger, with a market capitalization of $187.29M compared with $176.33M for Vogenx (VOGX).

Are Cartesian Therapeutics and Vogenx in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons